AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Aprea Therapeutics reports positive results in Phase 1 ACESOT-1051 trial.
ByAinvest
Friday, Oct 24, 2025 8:34 am ET1min read
Aprea Therapeutics reported that 3 out of 4 patients achieved stable disease in heavily pretreated gastrointestinal and gynecologic malignancies at the 100 mg APR-1051 dose level. Disease stabilization was observed in patients with tumors harboring mutations relevant to WEE1 kinase inhibition. Dose escalation continues, with patients now enrolling in the 150 mg cohort. Preliminary results from the ACESOT-1051 trial will be featured in a poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet